Friedberg C E, Janssen M J, Heine R J, Grobbee D E
Department of Internal Medicine, Ziekenhuis der Vrije Universiteit, Amsterdam, The Netherlands.
Diabetes Care. 1998 Apr;21(4):494-500. doi: 10.2337/diacare.21.4.494.
Hypertriglyceridemia is associated with cardiovascular disease in diabetes. Fibrates effectively lower, but do not always normalize, serum triglyceride levels. Fish oil supplements may then be added to lower serum triglyceride levels. Doubt remains whether the net effect of fish oil intake on glycemic control is beneficial in diabetes. We therefore performed a meta-analysis from published clinical trials.
Data sources were Medline (Cologne, Germany), Excerpta Medica, Current Contents, review articles, and published reference lists. Publications of 26 trials were selected, and all trials included more than five diabetes (IDDM and NIDDM) patients and addressed the effects of fish oil (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) on serum lipids and glucose tolerance. We (C.E.F., M.J.F.M.J.) extracted data independently based on predetermined criteria. Studies were classified according to design.
All studies combined showed a decrease in mean triglyceride concentrations in association with fish oil: -0.60 mmol/l (95% CI, -0.84 to -0.33, P < 0.01) and a slight but significant increase in serum LDL cholesterol: 0.18 mmol/l (95% CI, 0.04-0.32, P = 0.01), with both findings most prominent in NIDDM. No significant changes in HbA1c percentages occurred in diabetic subjects treated with fish oil. Fasting blood glucose levels were increased with borderline significance in NIDDM subjects (0.43 mmol/l [95% CI, 0.00-0.87], P = 0.06) and were significantly lower in IDDM subjects (-1.86 mmol/l [95% CI, -3.1 to -0.61], P < 0.05). Significant dose-response effects of EPA (g/day) on HbA1c and triglycerides and of DHA (g/day) on fasting blood glucose levels, HbA1c, and triglycerides were demonstrated only in NIDDM subjects.
The use of fish oil has no adverse affects on HbA1c in diabetic subjects and lowers triglyceride levels effectively by almost 30%. However, this may be accompanied by a slight increase in LDL cholesterol concentration. Fish oil may be useful in treating dyslipidemia in diabetes.
高甘油三酯血症与糖尿病患者的心血管疾病相关。贝特类药物能有效降低血清甘油三酯水平,但不一定能使其恢复正常。此时可添加鱼油补充剂以降低血清甘油三酯水平。鱼油摄入对糖尿病患者血糖控制的净效应是否有益仍存在疑问。因此,我们对已发表的临床试验进行了一项荟萃分析。
数据来源为医学索引数据库(德国科隆)、医学文摘数据库、现刊目次数据库、综述文章以及已发表的参考文献列表。选取了26项试验的出版物,所有试验纳入的糖尿病(1型糖尿病和2型糖尿病)患者均超过5例,并探讨了鱼油(二十碳五烯酸[EPA]和二十二碳六烯酸[DHA])对血脂和葡萄糖耐量的影响。我们(C.E.F., M.J.F.M.J.)根据预定标准独立提取数据。研究根据设计进行分类。
所有研究综合显示,服用鱼油后平均甘油三酯浓度降低:-0.60 mmol/l(95%可信区间,-0.84至-0.33,P<0.01),血清低密度脂蛋白胆固醇略有但显著升高:0.18 mmol/l(95%可信区间,0.04 - 0.32,P = 0.01),这两个结果在2型糖尿病患者中最为显著。接受鱼油治疗的糖尿病患者糖化血红蛋白百分比无显著变化。2型糖尿病患者空腹血糖水平有边缘性显著升高(0.43 mmol/l [95%可信区间,0.00 - 0.87],P = 0.06),而1型糖尿病患者空腹血糖水平显著降低(-1.86 mmol/l [95%可信区间,-3.1至-0.61],P<0.05)。仅在2型糖尿病患者中显示出二十碳五烯酸(克/天)对糖化血红蛋白和甘油三酯以及二十二碳六烯酸(克/天)对空腹血糖水平、糖化血红蛋白和甘油三酯有显著的剂量反应效应。
糖尿病患者使用鱼油对糖化血红蛋白无不良影响,可有效降低甘油三酯水平近30%。然而,这可能伴随着低密度脂蛋白胆固醇浓度略有升高。鱼油可能有助于治疗糖尿病患者的血脂异常。